ReviewJournal of neuro-oncology2017
The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
Review in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.Neurosurgical review · 2020Pooled it
- Reconstructing the molecular life history of gliomas.Acta neuropathologica · 2018Pooled it
- Implications of canonical histone H3.1 and histone variant H3.3 in cancer.Open biology · 2025Review
- H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series.Acta neurochirurgica · 2023Article
- Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives.Cancers · 2022Review
- Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021Article
- Beyond guidelines: analysis of current practice patterns of AANS/CNS tumor neurosurgeons.Journal of neuro-oncology · 2021Review
- Article
- Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults.Quantitative imaging in medicine and surgery · 2021Article
- Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.Journal of neuro-oncology · 2019Article
- Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities.Diagnostic pathology · 2019Review
- Emerging roles of telomeric chromatin alterations in cancer.Journal of experimental & clinical cancer research : CR · 2019Review
- When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM.Current neurology and neuroscience reports · 2018Review
- Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Article
- Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.Virchows Archiv : an international journal of pathology · 2017Article
- Review
- Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.Frontiers in oncology · 2017Review
- H3K27M-mutant, hemispheric diffuse glioma in an adult patient with prolonged survival.Neuro-oncology advancesArticle
- Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults.Neuro-oncology advancesArticle
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Genetic profiling is an increasingly useful tool for sub-classification of gliomas in adults and children. Specific gene mutations, structural rearrangements, DNA methylation patterns, and gene expression profiles are now recognized to define molecular subgroups of gliomas that arise in distinct anatomic locations and patient age groups, and also provide a better prediction of clinical outcomes for glioma patients compared to histologic assessment alone. Understanding the role of these distinctive genetic alterations in gliomagenesis is also important for the development of potential targeted therapeutic interventions. Mutations including K27M and G34R/V that affect critical amino acids within the N-terminal tail of the histone H3 variants, H3.3 and H3.1 (encoded by H3F3A and HIST1H3B genes), are prime examples of mutations in diffuse gliomas with characteristic clinical associations that can help diagnostic classification and guide effective patient management. These histone H3 mutations frequently co-occur with inactivating mutations in ATRX in association with alternative lengthening of telomeres. Telomere length can also be maintained through upregulation of telomerase reverse transcriptase (TERT) expression driven by mutation within the TERT gene promoter region, an alteration most commonly found in oligodendrogliomas and primary glioblastomas arising in adults. Interestingly, the genetic alterations perturbing histone and telomere function in pediatric gliomas tend to be different from those present in adult tumors. We present a review of these mutations affecting the histone code and telomere length, highlighting their importance in prognosis and as targets for novel therapeutics in the treatment of diffuse gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.